Are Dental Implants Suitable for Patients Taking Osteoporosis Medication?

There is a particular moment in a consultation that experienced dental teams learn to watch for. A patient hands over a medication list, and somewhere near the bottom is a weekly tablet she has taken for six years and did not think worth mentioning, because it is "just for bones".

That tablet is frequently the most consequential item on the page. Antiresorptive medication — bisphosphonates, denosumab and related drugs — works by slowing bone resorption, which is exactly what makes it effective for osteoporosis and exactly what makes jaw surgery a more careful proposition.

This article explains the mechanism, how risk is actually assessed, and why the answer for most osteoporosis patients is a considered yes rather than a reflexive no. It also explains, emphatically, why you should never stop this medication on your own initiative.

Does antiresorptive medication rule out implant treatment?

Antiresorptive medication does not automatically rule out implant treatment, but it requires individual risk assessment and, in most cases, liaison with the prescribing doctor. These drugs reduce bone turnover, and turnover is part of how the jaw repairs itself after surgery. There is a recognised, uncommon condition in which jawbone exposed by surgery or extraction fails to heal. The level of concern varies considerably: patients on oral medication for osteoporosis are in a substantially lower risk category than patients receiving high-dose intravenous treatment in an oncology setting. Many patients in the former group proceed with implant treatment following an informed discussion and with preventive measures in place.

Taken orally — commonly weekly or monthly — or given by infusion. They bind to bone mineral and are taken up by osteoclasts, inhibiting their activity. A key characteristic is that they persist in bone for a long period after the last dose, which is why a drug stopped years ago remains relevant.

Given by subcutaneous injection, usually every six months for osteoporosis. It works through a different mechanism, inhibiting a signalling pathway required for osteoclast formation and function. Unlike bisphosphonates it does not accumulate in bone, and its effect diminishes after the injection interval — but bone turnover rebounds when it is stopped, which is one reason stopping is not a decision to take lightly.

Romosozumab and other newer treatments have their own profiles. Selective oestrogen receptor modulators and parathyroid hormone analogues work differently again. All should be disclosed.

Two features make the jaws a particular case.

High turnover. Alveolar bone remodels considerably faster than most of the skeleton, particularly under functional load. Anything that slows turnover has a proportionally greater effect here.

Direct exposure. The jaws are separated from a heavily colonised environment by a thin layer of mucosa. Any surgical wound, extraction socket or denture ulcer creates a communication between the mouth and the bone. Elsewhere in the body, bone is not routinely exposed to bacteria in this way.

Where healing is impaired, bone can remain exposed and fail to resolve. This condition — medication-related osteonecrosis of the jaw — is uncommon, particularly in osteoporosis patients on oral therapy, but it is difficult to manage, which is why prevention is emphasised so strongly.

Risk is not a single category. It is stratified according to several factors.

• Indication. Osteoporosis doses are substantially lower than oncology doses. This is the biggest single differentiator.

• Route. Oral administration is associated with lower risk than intravenous or injected administration.

• Duration. Longer cumulative exposure is associated with higher risk. A threshold of several years is often cited as a point at which the discussion becomes more careful.

• Concurrent medication. Corticosteroids and antiangiogenic drugs compound the risk.

• Other patient factors. Smoking, poorly controlled diabetes, poor oral hygiene, active periodontal disease and immunosuppression all increase concern.

• Nature of the procedure. Extraction and implant placement involve bone; a filling or a crown does not.

Your dental team will normally write to your prescribing doctor to confirm the drug, dose, route, duration and the reason it was prescribed before planning surgery.

Where implant treatment proceeds, the plan is adapted:

• Optimise oral health first. Any decay treated, gum disease stabilised, unrestorable teeth dealt with. Our gum disease treatment page explains this stage, and regular hygiene visits support it long term.

• Atraumatic surgical technique. Minimising bone trauma, controlling heat, achieving good soft tissue closure over the site.

• Limited or staged surgery. Treating one area at a time rather than multiple quadrants in a single session.

• Avoiding extensive grafting where the risk profile is higher.

• Considering alternatives. A conventional bridge or a well-made denture avoids bone surgery altogether, though a denture that rubs can itself cause an ulcer over bone, so fit must be reviewed carefully.

• Antimicrobial and perioperative measures as indicated by current guidance.

• Explicit informed consent covering the specific risk, in writing.

• Closer follow-up than for a standard implant patient, with prompt review of any site that has not healed as expected.

Our clinically-led guide to implants describes the standard pathway for comparison, and our companion article on menopause, bone medication and implants covers the wider context.

This point deserves its own section because it is the most common and most dangerous misunderstanding.

Stopping antiresorptive medication carries a real fracture risk. With denosumab in particular, discontinuation is associated with a rebound increase in bone turnover and a recognised risk of vertebral fracture. The benefit of a temporary interruption before dental surgery — sometimes called a drug holiday — is debated and not firmly established.

Any decision about pausing, altering or timing this medication belongs to the prescribing doctor, taking your fracture risk into account. Your dental team's role is to provide the information about the planned procedure and to liaise, not to advise you to stop.

Prevention is disproportionately valuable in this group, because it avoids the surgery that carries the risk.

• Attend regular examinations so that problems are found while they can be treated without extraction. Our article on deep decay reaching the nerve explains why early detection matters.

• Maintain thorough daily cleaning, including interdentally.

• Attend hygienist appointments at the interval advised. See our dental hygiene page.

• Report any denture that rubs — an ulcer over the ridge in a patient on these medications should be assessed promptly, not tolerated.

• Do not smoke.

• Ideally, have a dental assessment before starting antiresorptive medication, so that any necessary extractions can be completed first. Ask your doctor about this if treatment is being planned.

The NHS provides general information about dental implants at nhs.uk.

Seek assessment if:

• You take, or have previously taken, any medication for bone density and are considering implants.

• You are about to start such medication — ideally arrange a dental check first.

• You need an extraction and take antiresorptive medication.

• You have an area of gum that has not healed, exposed bone, a persistent ulcer, altered sensation or unexplained jaw pain — these warrant prompt assessment.

• A denture is rubbing or causing a sore spot.

• You have been declined implant treatment and would like the reasoning explained.

• Antiresorptive medication must always be disclosed, including drugs stopped years ago.

• These drugs slow bone turnover, which is part of how the jaw heals after surgery.

• The jaws are distinctive because they remodel rapidly and are directly exposed to oral bacteria.

• Risk is stratified by indication, route, duration, concurrent medication and patient factors.

• Osteoporosis patients on oral therapy are in a substantially lower risk group than oncology patients on intravenous therapy.

• Never stop or alter this medication without instruction from the prescribing doctor.

• Where surgery proceeds, planning includes optimising oral health first, atraumatic technique and closer follow-up.

• Prevention matters more in this group precisely because it avoids the procedures that carry the risk.

Osteoporosis medication changes the way jaw surgery is planned, not whether it is possible. For most patients taking oral therapy for osteoporosis, implant treatment can be discussed sensibly, with the risk quantified, the consent explicit and the preventive work done first.

What it always requires is complete disclosure and a willingness on the dental team's part to write to your doctor. If you take medication for bone density and would like to discuss replacing missing teeth, you can arrange an appointment with our team at 22 Wimpole St, London W1G 8GQ, or telephone 020 7183 0692.

Dental symptoms and treatment options should always be assessed individually during a clinical examination.

This article is for general educational information only and is not professional dental advice, diagnosis, or a treatment recommendation. Information here is general and cannot replace an in-person assessment by a qualified, GDC-registered dental professional. Symptoms, suitability, fees, timelines, and outcomes vary according to individual clinical circumstances. If you have pain, swelling, or other concerning symptoms, seek prompt professional dental care. Always request a written treatment plan and cost estimate before proceeding with treatment.

Written Date: 25 August 2026

Next Review Date: 25 August 2027